vs
REPLIGEN CORP（RGEN）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP自由现金流更多（$17.6M vs $-139.5M）。过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -100.0%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
RGEN vs RVMD — 直观对比
营收规模更大
RGEN
是对方的Infinity倍
$0
自由现金流更多
RGEN
多$157.1M
$-139.5M
两年增速更快
RGEN
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $197.9M | $0 |
| 净利润 | $13.3M | $-194.6M |
| 毛利率 | 52.5% | — |
| 营业利润率 | 9.0% | — |
| 净利率 | 6.7% | — |
| 营收同比 | 13.6% | — |
| 净利润同比 | 143.9% | -20.4% |
| 每股收益（稀释后） | $0.24 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGENRVMD
| Q4 25 | $197.9M | — | ||
| Q3 25 | $188.8M | — | ||
| Q2 25 | $182.4M | — | ||
| Q1 25 | $169.2M | — | ||
| Q4 24 | $174.1M | $0 | ||
| Q3 24 | $154.9M | $0 | ||
| Q2 24 | $154.1M | $0 | ||
| Q1 24 | $151.3M | $0 |
净利润RGENRVMD
| Q4 25 | $13.3M | — | ||
| Q3 25 | $14.9M | — | ||
| Q2 25 | $14.9M | — | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $-30.3M | $-194.6M | ||
| Q3 24 | $-654.0K | $-156.3M | ||
| Q2 24 | $3.3M | $-133.2M | ||
| Q1 24 | $2.1M | $-116.0M |
毛利率RGENRVMD
| Q4 25 | 52.5% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 50.0% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 26.1% | — | ||
| Q3 24 | 50.0% | — | ||
| Q2 24 | 49.8% | — | ||
| Q1 24 | 49.5% | — |
营业利润率RGENRVMD
| Q4 25 | 9.0% | — | ||
| Q3 25 | 8.9% | — | ||
| Q2 25 | 7.6% | — | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -17.7% | — | ||
| Q3 24 | -5.1% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 1.3% | — |
净利率RGENRVMD
| Q4 25 | 6.7% | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 8.2% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | -17.4% | — | ||
| Q3 24 | -0.4% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 1.4% | — |
每股收益（稀释后）RGENRVMD
| Q4 25 | $0.24 | — | ||
| Q3 25 | $0.26 | — | ||
| Q2 25 | $0.26 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $-0.55 | $-1.13 | ||
| Q3 24 | $-0.01 | $-0.94 | ||
| Q2 24 | $0.06 | $-0.81 | ||
| Q1 24 | $0.04 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $767.6M | $2.3B |
| 总债务越低越好 | $542.2M | — |
| 股东权益账面价值 | $2.1B | $2.3B |
| 总资产 | $2.9B | $2.6B |
| 负债/权益比越低杠杆越低 | 0.26× | — |
8季度趋势，按日历期对齐
现金及短期投资RGENRVMD
| Q4 25 | $767.6M | — | ||
| Q3 25 | $748.7M | — | ||
| Q2 25 | $708.9M | — | ||
| Q1 25 | $697.2M | — | ||
| Q4 24 | $757.4M | $2.3B | ||
| Q3 24 | $784.0M | $1.5B | ||
| Q2 24 | $809.1M | $1.6B | ||
| Q1 24 | $780.6M | $1.7B |
总债务RGENRVMD
| Q4 25 | $542.2M | — | ||
| Q3 25 | $537.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $525.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RGENRVMD
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | $2.3B | ||
| Q3 24 | $2.0B | $1.6B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $2.0B | $1.7B |
总资产RGENRVMD
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $2.9B | — | ||
| Q4 24 | $2.8B | $2.6B | ||
| Q3 24 | $2.8B | $1.8B | ||
| Q2 24 | $2.9B | $1.8B | ||
| Q1 24 | $2.8B | $1.9B |
负债/权益比RGENRVMD
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.7M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $17.6M | $-139.5M |
| 自由现金流率自由现金流/营收 | 8.9% | — |
| 资本支出强度资本支出/营收 | 4.1% | — |
| 现金转化率经营现金流/净利润 | 1.93× | — |
| 过去12个月自由现金流最近4个季度 | $93.9M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流RGENRVMD
| Q4 25 | $25.7M | — | ||
| Q3 25 | $48.1M | — | ||
| Q2 25 | $28.6M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $39.2M | $-138.3M | ||
| Q3 24 | $49.3M | $-130.4M | ||
| Q2 24 | $42.2M | $-128.2M | ||
| Q1 24 | $44.7M | $-160.6M |
自由现金流RGENRVMD
| Q4 25 | $17.6M | — | ||
| Q3 25 | $43.4M | — | ||
| Q2 25 | $21.5M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $33.6M | $-139.5M | ||
| Q3 24 | $42.3M | $-133.9M | ||
| Q2 24 | $37.4M | $-130.6M | ||
| Q1 24 | $36.4M | $-163.7M |
自由现金流率RGENRVMD
| Q4 25 | 8.9% | — | ||
| Q3 25 | 23.0% | — | ||
| Q2 25 | 11.8% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 27.3% | — | ||
| Q2 24 | 24.3% | — | ||
| Q1 24 | 24.0% | — |
资本支出强度RGENRVMD
| Q4 25 | 4.1% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 3.1% | — | ||
| Q1 24 | 5.5% | — |
现金转化率RGENRVMD
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.57× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 12.70× | — | ||
| Q1 24 | 21.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
